We are live on ! Find out more
GERM

Amplify Treatments, Testing and Advancements ETF
GERM

Delisted

GERM was delisted on the 5th of September, 2024.

Back to rankings

Fund managers haven’t disclosed any holdings of GERM yet.

GERM Hedge Fund Activity: Q4 2024 in Review

0 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2024, worth a combined $0 — down 100% from $3.83K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GERM and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was IFP Advisors, exiting entirely with an estimated $3.83K sold.

  • 0 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2024, down from 1 in Q3 2024.
  • Funds reported $0 of Amplify Treatments, Testing and Advancements ETF stock for Q4 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2024 and 1 closed out, a net change of -1 holder.
  • The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2024 was IFP Advisors, an estimated $3.83K sold.

Based on aggregated 13F filings for Q4 2024.